Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie-Sarah Dilhuydy

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Expert Opinion on Biological Therapy|June 15, 2005
Interferon alpha for the treatment of advanced renal cancerAlain Ravaud, Marie-Sarah Dilhuydy
British Journal of Haematology|April 12, 2007
Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemiaMarie-Sarah Dilhuydy, Thomas Jouary, Hélène Demeaux, et al.
The Lancet. Haematology|August 27, 2021
eBEACOPP or A-AVD in advanced Hodgkin lymphoma: (re)thinking the toxicities in the PET-driven strategies eraJean Galtier, Pauline Brice, Krimo Bouabdallah, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 5, 2010
Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS StudyMarie-Sarah Dilhuydy, Thierry Lamy, Charles Foussard, et al.
Intensive Care Medicine|November 9, 2006
Decrease in circulating dendritic cells predicts fatal outcome in septic shockOlivier Guisset, Marie-Sarah Dilhuydy, Rodolphe Thiébaut, et al.
Journal of Leukocyte Biology|February 22, 2023
Elevated levels of circulatory follicular T helper cells in chronic lymphocytic leukemia contribute to B cell expansionCorentin Le Saos-Patrinos, Séverine Loizon, Atika Zouine, et al.
Annales De Biologie Clinique|October 21, 2023
Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patientsVictor-Emmanuel Brett, Marie-Sarah Dilhuydy, Nicolas Lechevalier, et al.
Leukemia & Lymphoma|July 28, 2020
Vinblastine for elderly and frail patients with Hodgkin lymphomaLucie Meynard, Jean Galtier, Simon Favre, et al.
British Journal of Haematology|February 11, 2019
Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapiesJan A Burger, Paula Cramer, Paul M Barr, et al.
Plos One|May 12, 2009
The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cellsGwendaline Guidicelli, Benjamin Chaigne-Delalande, Marie-Sarah Dilhuydy, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Expert Opinion on Biological Therapy|June 15, 2005
Interferon alpha for the treatment of advanced renal cancerAlain Ravaud, Marie-Sarah Dilhuydy
British Journal of Haematology|April 12, 2007
Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemiaMarie-Sarah Dilhuydy, Thomas Jouary, Hélène Demeaux, et al.
The Lancet. Haematology|August 27, 2021
eBEACOPP or A-AVD in advanced Hodgkin lymphoma: (re)thinking the toxicities in the PET-driven strategies eraJean Galtier, Pauline Brice, Krimo Bouabdallah, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 5, 2010
Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS StudyMarie-Sarah Dilhuydy, Thierry Lamy, Charles Foussard, et al.
Intensive Care Medicine|November 9, 2006
Decrease in circulating dendritic cells predicts fatal outcome in septic shockOlivier Guisset, Marie-Sarah Dilhuydy, Rodolphe Thiébaut, et al.
Journal of Leukocyte Biology|February 22, 2023
Elevated levels of circulatory follicular T helper cells in chronic lymphocytic leukemia contribute to B cell expansionCorentin Le Saos-Patrinos, Séverine Loizon, Atika Zouine, et al.
Annales De Biologie Clinique|October 21, 2023
Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patientsVictor-Emmanuel Brett, Marie-Sarah Dilhuydy, Nicolas Lechevalier, et al.
Leukemia & Lymphoma|July 28, 2020
Vinblastine for elderly and frail patients with Hodgkin lymphomaLucie Meynard, Jean Galtier, Simon Favre, et al.
British Journal of Haematology|February 11, 2019
Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapiesJan A Burger, Paula Cramer, Paul M Barr, et al.
Plos One|May 12, 2009
The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cellsGwendaline Guidicelli, Benjamin Chaigne-Delalande, Marie-Sarah Dilhuydy, et al.
Pageof 5